TransPot (The Translational Research Network for Prostate Cancer) is an innovative programme designed to tackle incurable prostate cancer (PC). Prostate cancer is the most commonly diagnosed cancer in Europe, and is the third most common cause of cancer death. First-line therapy for PC is androgen deprivation therapy (ADT), however after around two or three years, resistance to this treatment manifests leading to castration-resistant prostate cancer (CRPC). CRPC is more metastatic and aggressive, and further treatment via chemotherapy gives only a modest survival benefit to patients. There is therefore an urgent need for more effective novel therapies for incurable PC.
TransPot is a four-year Horizon 2020 Marie Skłodowska-Curie grant funded by the European Commission that is focused on achieving this. The network is composed of academic and industrial institutions from the United Kingdom, Finland, Germany, Greece and The Netherlands. TransPot will integrate the leading research scientists and laboratories in Europe within this research field to recruit 11 early stage researchers (ESRs) and offer them the unique opportunity to perform top-level and high impact research.
This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 721746